Ekso Bionics price target raised to $10 from $9 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Ekso Bionics to $10 from $9 and keeps a Buy rating on the shares. The company’s preannounced Q4 revenue shows strong momentum, the analyst tells investors in a research note. This reflects the success of management’s strategy to focus on executing multi-unit orders with large network operators and the contribution of Indego Personal, the company’s exoskeleton for home and community use, says the firm.